Lumos Pharma — Q2 2024 Earnings Presentation
8 slides from Lumos Pharma's earnings presentation, Aug 1, 2024
Slide 1: Q2 2024 Financial Results, Clinical & Strategic Update
1 Q2 2024 Financial Results, Clinical & Strategic Update August 1, 2024
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward- looking statements within the meaning of The Private Securities Litigation Reform
Slide 3: Agenda
3 Agenda • Lisa Miller, Vice President of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Lori Lawley, Chief Fina
Slide 4: Clinical and Strategic Update
4 • FDA supportive of registrational path forward • FDA recognized LUM-201, a growth hormone secretagogue, as a novel growth promoter • FDA acknowledged the use of a placebo-controlled clinical trial design as an appropriate option for a LUM-201 Phase 3 trial • Engaged investment bank to assist the
Slide 5: Data Presented at Medical Conferences Highlight Oral LUM-201 Potential in PGHD
5 Data Presented at Medical Conferences Highlight Oral LUM-201 Potential in PGHD ENDO: Endocrine Society Annual Meeting PES: Pediatric Endocrine Society Annual Meeting GRS: Growth Hormone Research Society ECE: European Congress of Endocrinology • LUM-201’s pulsatile pattern of growth hormone secreti
Slide 6: Proposed Phase 3 trial design for LUM-201
6 12-month, 2:1 randomization, double-blind, single arm cross-over design with all placebo patients switched to LUM-201 at 6 months, who then continue for an additional 6 months on treatment Screening Up to 60 days LUM-201 1.6 mg/kg/day 12 months N ~100 Placebo control 6 months N= approximately 40 -
Slide 7: Lumos Pharma Pro Forma Financial Information as of June 2024
7 Lumos Pharma Pro Forma Financial Information as of June 30, 2024 Values in USD LUMO Cash, cash equivalents, & short-term investments to support operations into Q1 2025. Q2 2024 R&D Expense $4.6M G&A Expense $3.7M Net Loss $7.6M Cash & Equivalents $16.8M Shares Outstanding 8,123,186
Slide 8: Investment Thesis
8 • Positive End-of-Phase 2 meeting with FDA held early Q2 2024 regarding Phase 3 program • Initiation of Phase 3 trial anticipated Q2 2025 • PEM strategy de-risks patient selection, identifying likely LUM-201 responders3 • Phase 2 trials met all primary and secondary endpoints • Phase 2 data demons